TEVA-PINDOLOL TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PINDOLOL

から入手可能:

TEVA CANADA LIMITED

ATCコード:

C07AA03

INN（国際名）:

PINDOLOL

投薬量:

10MG

医薬品形態:

TABLET

構図:

PINDOLOL 10MG

投与経路:

ORAL

パッケージ内のユニット:

100/500

処方タイプ:

Prescription

治療領域:

BETA-ADRENERGIC BLOCKING AGENTS

製品概要:

Active ingredient group (AIG) number: 0112362003; AHFS:

認証ステータス:

APPROVED

承認日:

2011-09-15

製品の特徴

1
PRODUCT MONOGRAPH
PR
TEVA-PINDOLOL
Pindolol
5 mg, 10 mg and 15 mg Tablets
USP
Antihypertensive/Antianginal Agent
Teva Canada Limited
Date of Revision:
30 Novopharm Court
April 23, 2019
Toronto, Ontario
Canada M1B 2K9
www.tevacanada.com
Control No: 225972
2
NAME OF DRUG
Pr
TEVA-PINDOLOL
Pindolol
5 mg, 10 mg and 15 mg Tablets
USP
THERAPEUTIC CLASSIFICATION
Antihypertensive/Antianginal Agent
ACTIONS
TEVA-PINDOLOL (pindolol) is a β-adrenergic-receptor-blocking agent
which possesses partial
agonist activity (intrinsic sympathomimetic activity - I.S.A.). It is
used in the treatment of
hypertension and/or the prophylaxis of angina pectoris.
Hypertension
The mechanism of the antihypertensive effect of pindolol has not been
established. Among the
factors that may be involved are:
a)
competitive ability to antagonize catecholamine-induced tachycardia at
the β-receptor
sites in the heart, thus decreasing cardiac output
b)
a reduction in total peripheral resistance
c)
inhibition of the vasomotor centres
d)
inhibition of renin release by the kidneys
Angina Pectoris
The mechanism of the antianginal effect of pindolol has not been
established. Pindolol may
reduce the oxygen requirement of the heart at any level of effort by
blocking catecholamine-
induced increases in the heart rate, systolic blood pressure, and the
velocity and extent of
myocardial contraction. However, oxygen requirements may be increased
by such actions as
increases in left ventricular fibre length, end diastolic pressure and
the systolic ejection period.
When the net effect is beneficial in patients with angina, it
manifests itself during exercise or
stress by delaying the onset of pain and reducing the incidence and
severity of anginal attacks.
In man, orally-administered pindolol is rapidly and almost completely
absorbed (≥ 95%) from
the gastrointestinal tract. The mean absolute bioavailability after
oral administration is about 87-
92%. Plasma levels of 10 to 30 nanogram/mL are associated with its
therapeutic efficacy.
Following single dose adminis